Jude Nwokike is Vice President at USP and the Director of the Promoting the Quality of Medicines Plus (PQM+) Program, a five-year cooperative agreement between the United States Agency for International Development (USAID) and USP. He is a leader in global health program management with more than 20 years of experience in medical products regulation and quality assurance systems strengthening.
Prior to his current role, Mr. Nwokike provided strategic leadership and direction for the implementation of the predecessor PQM program, a large and technically complex 10-year, $110M global program. Under his leadership, the PQM Program went through extensive transformation in management, technical delivery, and operations. He guided the PQM leadership team, country directors, managers, and about 90 staff members and consultants in more than 30 countries in Africa, Asia, Latin America and Eastern Europe to develop sustainable and self-reliant regulatory and quality assurance systems and advance manufacturing of quality-assured medical products to meet priority global health objectives.
Before joining USP, Mr. Nwokike served as the U.S. Food and Drug Administration’s (FDA) liaison working closely with the Center for Drug Evaluation and Research (CDER) on the PEPFAR antiretroviral drugs (ARVs) tentative approval program. As FDA’s point of contact, he coordinated activities dealing with pharmaceutical companies seeking to participate in the expedited review process for ARVs and liaised with the World Health Organization to share information on FDA tentatively approved and approved ARVs. Prior to FDA, he worked for around 10 years with the USAID-funded programs of Management Sciences for Health (MSH), around 10 years in the pharmaceutical industry, and two years with the government of Botswana.
Mr. Nwokike is a Pharmacist with postgraduate degrees in pharmaceutical sciences and public health. He has served on several international expert advisory and review committees, professional scientific associations, and technical working groups, and he is a leading global advocate for regulatory systems strengthening and pharmaceutical workforce development.